The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
Patient burden associated with acute & chronic resistant infections
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...